Is Meta-Analysis a Sign of Something Big on the Horizon for GID?

All signs are pointing to something big on the horizon for GI Dynamics and its embattled obesity and type 2 diabetes treatment technology. The most recent guidepost from the Lexington, MA-based company came Thursday, when it announced results were being published from a meta-analysis of the EndoBarrier. Results show the device was able to impact weight loss and insulin resistance improvement. The research is titled “Effects of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Type 2 Diabetic Patients with Obesity: A Meta-analysis with Secondary Analysis on Weight Loss and Hormonal Changes,” and has been published in Diabetes Care, the journal of the American Diabetes Association. The results were first presented by Pichamol Jirapinyo, M.D., Division of Gastroenterology, Hepatology and Endoscopy at Brigham and Women’s Hospital and Harvard Medical School in Boston during Digestive Disease Week (DDW) in May of last year. GI Dynamics' EndoBarrier works by creating a barrier between food and the wall of the small intestine and thereby changes metabolic pathways by controlling how food moves through the digestive system. The effects are supposed to be similar to gastric bypass surgery, but without the surgical procedure and hospital stay. The firm's meta-analysis is comprised of 17 published studies that evaluate EndoBarrier outcomes in patients with type 2 diabetes and obesity. Primary outcomes of the meta-analysis were change in hemoglobin A1c (HbA1c) and homeosta...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Source Type: news